Who is sponsoring NCT05433870?

NCT05433870 is sponsored by Dunjin Chen.

What drugs are being tested in NCT05433870?

Interventions in NCT05433870: Whether the PE or E patient combined with PRES.

What condition does NCT05433870 study?

NCT05433870 studies Posterior Reversible Encephalopathy Syndrome, Inflammatory Biomarkers, Neutrophil-lymphocyte Ratio.

Is NCT05433870 still recruiting?

NCT05433870 is currently completed. Last updated 3 August 2022.

Last reviewed 2022-08-03 · How we verify

NCT05433870

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inflammatory Biomarkers for the Diagnosis of oPRES

Completed Last updated 3 August 2022

What this trial tests

trial testing Whether the PE or E patient combined with PRES in Posterior Reversible Encephalopathy Syndrome in 621 participants. Completed in 31 July 2022.

Timeline

1 July 2022

Primary endpoint
31 July 2022

31 July 2022

Quick facts

Lead sponsor	Dunjin Chen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	621
Start date	1 July 2022
Primary completion	31 July 2022
Estimated completion	31 July 2022
Sites	1 location across China

Drugs / interventions tested

Whether the PE or E patient combined with PRES

Conditions studied

Posterior Reversible Encephalopathy Syndrome — all drugs for Posterior Reversible Encephalopathy Syndrome →
Inflammatory Biomarkers — all drugs for Inflammatory Biomarkers →
Neutrophil-lymphocyte Ratio — all drugs for Neutrophil-lymphocyte Ratio →

Sponsor

Dunjin Chen — full company profile →

Who can join

Adults 16 to 50, female only, with Posterior Reversible Encephalopathy Syndrome or Inflammatory Biomarkers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to explore the inflammatory biomarkers for the diagnosis of obstetric posterior reversible encephalopathy syndrome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Dunjin Chen trials

Trials by the same sponsor.

NCT06684080 — The Effectiveness of a Care Bundle to Prevent Postpartum Hemorrhage After Cesarean Delivery · NA · not yet recruiting
NCT05310513 — The Predictors of ICU Admission of oPRES · completed
NCT05143710 — The Clinical and Prognostic Features of PRES · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05433870 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dunjin Chen
Last refreshed: 3 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05433870.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing